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INTRODUCTION
STATE OF THE ART
AIM
c
Duchenne muscular dystrophy (DMD)1 is the most severe and common myopathy, affecting one in every 3,500 newborn males.
THERAPEUTIC APPROACH DESIGN
CONCLUSIONS
Figure 1. Muscular degeneration in DMD6. A) Normal muscle histology. B) Early alterations such as necrosis. C) Late stage of myopathy with adipocyte
infiltration and fibrotic tissue. *, adipocytes; arrow, dystrophic fibers.
DMD is a recessive lethal X-linked disorder caused by the absence of dystrophin in muscle fibers. The
main function of dystrophin is to stabilize myofibers during muscle contractions. DMD is characterized
by progressive muscle degeneration, which is replaced with adipose and fibrotic connective tissue
(Fig.1). Central nervous system (CNS) and bones are also affected. The clinical progression of DMD is
reflected in Figure 2.
This disorder is caused by an alteration in the frameshift of the
dystrophin gene whereby result in a premature stop codon, which
could be generated by these three main categories (Fig.3).
There are currently no curative treatments for this disease, but different ameliorating therapeutic approaches are being studied. Table 1
shows current treatments and approaches for DMD1.
Figure 2. Clinical progression of DMD. Death is
due to a cardiorespiratory failure.
Figure 3. Genetic causes of DMD1
The size of the dystrophin gene is 2’4Mb, the biggest human gene. It
contains 79 exons that code for 14kb mRNA and has 7 isoforms1.
For these reasons, the treatment of DMD with gene therapy is difficult and still a challenge nowadays.
In this project, the most recent publications related
to DMD treatment and its therapeutic approaches,
either researches or clinical trials were studied.
Data has been obtained using the searching engine
Pubmed. The search was based in key words such as
Duchenne, gene therapy and iPSC. These articles
were read and summarized.
Afterwards, different strategies and methods were
compared based on risks and benefits and the best
one was selected and explained.
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PHARMACOLOGY
GENE THERAPY
OTHER APPROACHES DYSTROPHIN RESTORATION APPROACHES
Corticosteroids 
(prednisone)
Utrophin up regulators Miostatin blockers
Stop codon read-through 
drugs
Antisense oligonucleotides
Nucleases (ZFN, TALEN, 
CRISPR)
Function
Prolonged 
ambulation for about 
2 years.
utrophin could slow 
down DMD development
Muscle strength    
with hypertrophy 
and hyperplasia.
Introduction an amino acid at 
the premature stop codon to 
continue the mRNA translation.
Exon skipping due to the 
interaction with splicing 
signals in pre-mRNA.
Restoration of the dystrophin 
reading frame by micro-
deletion o micro-insertion.
There are lots of 
strategies to tackle 
DMD, either using 
viral vectors or 
without them.
Only in research.
Problems
Side effects such as 
weight gain and bone 
demineralization.
Drugs cannot    utrophin
sufficiently to suppress 
DMD symptoms.
Continuous 
administration.
Only useful for punctual 
mutation’s patients (10-30%).
Continuous administration.
Target design patient-specific
Difficulties to arrive to all the 
target locations using an in 
vivo approach.
Due to the severity and high
incidence of Duchenne disease, the
aim of this project is to
determinate the optimal
therapeutic approach restoring
muscle function and ameliorating
symptoms and life expectancy.
Table 1. Therapeutic state of the art of DMD1
Autologous ex vivo cell therapy In vivo gene therapy
Skin biopsy
Fibroblasts2
iPSC
iPSCDys
MyoblastDys
Myoblasts transplantation (MT)6
due to the 
high-density injections (HDI)
2-3 days
1 week
2-3 weeks
• Patient cells = donor cells immune response
• DMD patients have myoblasts or satellite cells
• Somatic cells iPSCs
- Same embryonic origin 
(mesenchyma)
- Easy to obtain, culture and 
expansion
- Simple nutritive request and 
culture viability
Oct4 mRNA
Klf4 mRNA
Sox2 mRNA
VPA
Administration timing:
CRISPR-Cas9 system5
Target locomotors muscles:
- Upper limb: deltoid, biceps, 
triceps, brachioradialis
- Lower limb: quadriceps, sartorius, 
tibialis anterior, biceps femoral, 
semimembranosus, 
semitendinosus, gastrocnemius
ex vivo 
gene therapy
reprogramming3,4
differentiation2,4
MyoD mRNA ( 3 days )
oncogenic risk
efficiency
clones selection
off-target5
Genetic complementation
• DMD patients’ cause of death: cardiorespiratory failure
• Target tissues: myocardium respiratory muscles
(differentiated cells)
• Minimal levels of functional dystrophin expression to
ameliorate symptoms of DMD: >40-50%
VECTOR1,7
Retrovirus and 
Lentivirus
Adenovirus
Adeno-associated viral 
vectors (AAV)
Non-viral
vectors
Infected replicative cells 
(lentivirus also quiescent)
Integrative vector
Insertional mutagenesis
Infected replicative and 
quiescent cells
Non-integrative vector
immunogenic
Infected replicative and 
quiescent cells
Non-integrative vector
immunogenic
efficiency
Target tissues’ tropism of AAVs serotypes7:
• AAV2/1: myocardium skeletal muscle (via IM)
• AAV2/8: myocardium skeletal muscle (via IV)
• AAV2/9: myocardium skeletal muscle (via IV)
encapsidation capacity: 4’7 kb (4’4 kb + 2x ITR) 1
CONSTRUCT DESIGN
cDNA dystrophin (14 kb)
• µDys: synthetic abbreviate
functional dystrophin.1
• miniCMV: ubiquous and
powerful promoter.
It is been silenciate in the liver
of large animals.
AAV2/9 also has a good tropism to liver and CNS, due to it can cross BHE7.
Alternative construct
mirR-T: targeting sequence of a tissue
specific microRNA.
microRNAs silence the expression of
mRNAs. If the construct has got the
targeting sequence of a CNS specific
miR-T, such as TS miR124, the transgen
will not express in this tissue.
It would be better to use tissue specific
promoters, such as MCK for skeletal
muscle or MLC2v for myocardium, but
they are too big for an AAV size.
Even though studies do not show any toxicity or side effect in these localizations, if in following studies it
detects someone, an alternative construct could be used.
Intravascular 
administration
Medium vein
single 
administration
IMMUNOLOGICAL REMARKS
• If the patient has anti-AAV antibodies before treatment, he cannot be accepted for the therapy
because the treatment is not going to be effective.
• Immunosuppressants have to be administrated until patient eliminates viral capsids.7
• Depending on the genetic alteration, the immune systems of patients could react against new
dystrophin (ex vivo cell therapy) or synthetic abbreviation dystrofin (in vivo gene therapy). For these
reason, some patients have to take immunosuppressant in the lifelong.6
• Nowadays, it does not exist a clinical strategy which completely restore healthy phenotype in Duchenne
patients.
• Nevertheless, an optimal therapeutic approach has been determinated. This one ameliorate locomotor
function and prolong life expectancy, like clinical characteristics of Becker muscular dystrophy patients.
• More studies in mice (mdx) and canine (cxmd) models are needed to further
develop this therapy.
